BIMEKIZUMAB

bimekizumab 160 mg/mL injection, 2 x 1 mL pen devices

BIMEKIZUMAB (13652M)

bimekizumab 160 mg/mL injection, 2 x 1 mL pen devices
13652M
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Whole body

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Face, hand, foot

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Whole body or Continuing treatment, Face, hand, foot - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 2 DPMQ: $3,395.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Bimzelx